Plain-English translation of NCT05919329 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is studying how a specific type of imaging scan (called a PSMA PET scan) changes when men with prostate cancer start taking hormone therapy. Researchers want to understand whether the early changes in these scans can predict how well the treatment will work and help guide future care decisions.
Doctors currently use hormone therapy to treat prostate cancer, but they don't yet know how quickly the disease responds to this treatment or what early signs predict long-term success. This study aims to find out whether the initial changes on imaging scans can help doctors better understand which patients will benefit most from their treatment.
You likely qualify if…
You likely don't qualify if…
You will receive three PSMA PET imaging scans: one before you start hormone therapy, one 8 days after starting the medication, and one 28 days after starting. These scans are part of your standard care, and researchers will track how the images change over time. You will be followed in the study for up to 5 years to see how your cancer responds to treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States